The case for evidence-based medicine for the association between hyperuricaemia and CKD
- PMID: 32313212
 - DOI: 10.1038/s41581-020-0288-3
 
The case for evidence-based medicine for the association between hyperuricaemia and CKD
Comment in
- 
  
  Reply to 'The case for evidence-based medicine for the association between hyperuricaemia and CKD'.Nat Rev Nephrol. 2020 Jul;16(7):422-423. doi: 10.1038/s41581-020-0289-2. Nat Rev Nephrol. 2020. PMID: 32313213 No abstract available.
 
Comment on
- 
  
  The case for uric acid-lowering treatment in patients with hyperuricaemia and CKD.Nat Rev Nephrol. 2019 Dec;15(12):767-775. doi: 10.1038/s41581-019-0174-z. Epub 2019 Jul 11. Nat Rev Nephrol. 2019. PMID: 31296965 Review.
 
References
- 
    
- Sato, Y. et al. The case for uric acid-lowering treatment in patients with hyperuricaemia and CKD. Nat. Rev. Nephrol. 15, 767–775 (2019). - DOI
 
 - 
    
- Tan, Y., Fu, J., Liang, M., Lin, Z. & Huang, J. Clinical observation of the effect of allopurinol to protect renal function in patients with diabetic nephropathy. Mod. Hosp. 11, 36–38 (2011).
 
 - 
    
- Yood, R. A., Ottery, F. D., Irish, W. & Wolfson, M. Effect of pegloticase on renal function in patients with chronic kidney disease: a post hoc subgroup analysis of 2 randomized, placebo-controlled, phase 3 clinical trials. BMC Res. Notes 7, 54 (2014). - DOI
 
 - 
    
- Downing, N. S., Aminawung, J. A., Shah, N. D., Krumholz, H. M. & Ross, J. S. Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005–2012. JAMA 311, 368–377 (2014). - DOI
 
 - 
    
- Djulbegovic, B. & Guyatt, G. H. Progress in evidence-based medicine: a quarter century on. Lancet 390, 415–423 (2017). - DOI
 
 
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
